DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2

Oncogene

Volumn 34, Issue 48, 2015, Pages 5869-5878

  Poirier, J T ^a   Gardner, E E ^a,b   Connis, N ^c   Moreira, A L ^a   De Stanchina, E ^a   Hann, C L ^c   Rudin, C M ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; NEUROGENIC DIFFERENTIATION FACTOR; PROTEIN BCL 2; PROTEIN P53; TAZEMETOSTAT; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR MASH1; EZH2 PROTEIN, HUMAN; MESSENGER RNA; POLYCOMB REPRESSIVE COMPLEX 2; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; EPIGENETICS; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HISTONE METHYLATION; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; LUNG CANCER CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL CELL LUNG CANCER; TRANSCRIPTION INITIATION SITE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CPG ISLANDS; DNA METHYLATION; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SMALL CELL LUNG CARCINOMA; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84948570001     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.38     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001; 28: 3-13.
4. Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y, et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One 2009; 4: e7835.
5. Madrigal PA, Manga GP, Palomero I, Gomez RG. VP16-213 combined with cisplatinum (CDDP) in the treatment of small cell carcinoma of the lung (SCLC). Cancer Chemother Pharmacol 1982; 7: 203-204.
6. Lara PN Jr., Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009; 27: 2530-2535.
7. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012; 44: 1111-1116.
8. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012; 44: 1104-1110.
9. Clinical Lung Cancer Genome Project, Network Genomic Medicine. A genomicsbased classification of human lung tumors. Sci Transl Med 2013; 5: 209ra153.
10. Cancer Genome Atlas Research Network, Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
11. Cancer Genome Atlas Network, Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
12. Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
13. Cancer Genome Atlas Research Network, Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
14. Kalari S, Jung M, Kernstine KH, Takahashi T, Pfeifer GP. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells. Oncogene 2013; 32: 3559-3568.
15. Rauch T, Pfeifer GP. Methylated-CpG island recovery assay: A new technique for the rapid detection of methylated-CpG islands in cancer. Lab Invest 2005; 85: 1172-1180.
16. Hann CL, Rudin CM. Fast, hungry and unstable: finding the Achilles' heel of smallcell lung cancer. Trends Mol Med 2007; 13: 150-157.
17. Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011; 43: 768-775.
18. Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. J Natl Cancer Instit 2013; 105: 1059-1065.
19. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985; 45: 2913-2923.
20. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009; 69: 3364-3373.
21. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC et al. Multiple-laboratory comparison of microarray platforms. Nat Methods 2005; 2: 345-350.
22. Berman BP, Weisenberger DJ, Aman JF, Hinoue T, Ramjan Z, Liu Y et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet 2012; 44: 40-46.
23. Jaffe AE, Murakami P, Lee H, Leek JT, Fallin MD, Feinberg AP et al. Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol 2012; 41: 200-209.
24. Gardner EE, Connis N, Poirier JT, Cope L, Dobromilskaya I, Gallia GL et al. Rapamycin rescues ABT-737 efficacy in small cell lung cancer. Cancer Res 2014; 74: 2846-2856.
25. Smith LT, Lin M, Brena RM, Lang JC, Schuller DE, Otterson GA et al. Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci USA 2006; 103: 982-987.
26. Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res 2010; 16: 4864-4875.
27. Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 2014; 506: 445-450.
28. Zouridis H, Deng N, Ivanova T, Zhu Y, Wong B, Huang D et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med 2012; 4: 156ra40.
29. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17: 510-522.
30. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-793.
31. Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropath 2012; 124: 547-560.
32. Chang CJ, Hung MC. The role of EZH2 in tumour progression. Brit J Cancer 2012; 106: 243-247.
33. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22: 5323-5335.
34. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-1558.
35. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012; 2: 798-811.
36. Ziller MJ, Gu H, Muller F, Donaghey J, Tsai LT, Kohlbacher O et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 2013; 500: 477-481.
37. Varley KE, Gertz J, Bowling KM, Parker SL, Reddy TE, Pauli-Behn F et al. Dynamic DNA methylation across diverse human cell lines and tissues. Genome Res 2013; 23: 555-567.
38. Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS One 2012; 7: e36530.
39. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003; 4: 181-189.
40. Wee ZN, Li Z, Lee PL, Lee ST, Lim YP, Yu Q. EZH2-mediated inactivation of IFN-gamma-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer. Cell Rep 2014; 8: 204-216.
41. Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol 2013; 9: 643-650.